Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01321021

Acronym

LoDi-Basel

Enrollment

Registered

2011-03-23

Start date

2011-03-31

Completion date

2011-08-31

Last updated

2012-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Memory, Long-Term, Memory, Short-Term

Brief summary

This project aims at identifying novel pharmacological targets for the treatment of memory disorders.

Detailed description

To investigate the effects of the histamine H1 receptor antagonist diphenhydramine and the angiotensin II receptor antagonist losartan on emotional and cognitive functions in healthy human subjects.

Interventions

DRUGLosartan, Diphenhydramine, Placebo

placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy * native or fluent German-speaking * BMI between 19 and 27 kg/m2 * able and willing to give written informed consent and comply with the requirements of the study protocol * willing to donate saliva sample for DNA-analysis * female: willing to perform a pregnancy test at the beginning of both test visits

Exclusion criteria

* acute or chronic psychiatric or somatic disorder * pathological ECG * known hypersensitivity to the IMP under investigation (losartan, diphenhydramine) * hypotension (RR \< 110/70 mmHg) * bradycardia (\< 50 bpm) * pregnancy, breast-feeding * long-term medication within last 3 months (oral contraceptives are disregarded) * smoking (\> 3 cigarettes per day) * concurrent participation in another study * participation in one of our previous studies using the same memory tests * inability to read and understand the participant's information

Design outcomes

Primary

Measure	Time frame	Description
Primary Outcome Measures	during cognitive testing at study days	Memory functions

Secondary

Measure	Time frame	Description
Secondary Outcome Measures	during cognitive testing at study days	sleepiness, mood, anxiety, attention, fluid intelligence

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026